General Electric Co. plans to keep its $4 billion life-sciences operations even as the manufacturing giant remakes itself around heavy industry.
GE is looking to expand investment in the fast-growing business, Healthcare Chief Executive Officer John Flannery said Friday at an investor meeting. Sales in life sciences, which makes products spanning chromatography, imaging and cell-therapy tools, will increase at least 10 percent this year, GE said.
“It’s a fundamentally attractive industry with growth and we have a very strong competitive position,’’ Flannery said. “We are certain this business grows faster inside of GE than it would grow outside.”